Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non Small Cell Lung Cancer Metastatic Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
Fit for systemic treatment (PS 0-2) according to standard of care.
No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.

Exclusion criteria

Prior/concomitant therapy for stage IV disease.
Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
Contraindications for MRI scan with contrast as per standard of care protocol of the institution.

Treatment and study plan

MRI

Diagnostic Test

MRI scan of the brain

Primary outcomes

Clinical value of the MRI

Time frame: up to 6 months after the MRI

Clinical value of the MRI evaluated by the treating thoracic oncologist and assessed by questionnaires completed on three timepoints.

Study contacts

Contact information is provided by the study sponsor or research team.

F. Bensch, MD, PhD

CONTACT

[email protected]

0031503616161

L.B.M. Hijmering, MD

CONTACT

[email protected]

0031503616161

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Registry information

Official study title

ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial

Acronym: VULCAN

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: May 18, 2023
Registry last updated: Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed